CEP certification confirms Brains Bio’s naturally-derived CBD pharmaceutical ingredient meets European Pharmacopoeia ...

The MarketWatch News Department was not involved in the creation of this content. HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing ...

Prime biotech buyout targets such as Revolution Medicines and BioCryst Pharmaceuticals have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.

BioMarin Pharmaceutical (NASDAQ:BMRN) executives used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to ...

The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the ...

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support ...

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a ...

LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...